Down Syndrome-Associated Alzheimer's

The latest sourced reporting on Down Syndrome-Associated Alzheimer's from Dementias Today: dated, and plain about what the evidence does and does not show.

The Alzheimer's test that arrives in the post

A multicenter European study put a finger prick against a needle in the arm, and asked whether a card of dried blood mailed at room temperature could carry the same signal. For people whose veins are hard to find, including adults with Down syndrome, the question is not academic.

The Injections That Missed: A Task Force Reckons With Gene Therapy in Dementia

Proceedings of the first EU-US CTAD Task Force on genetic therapies, published in the Journal of Prevention of Alzheimer's Disease, walk through what went wrong in adeno-associated virus trials for Alzheimer's and frontotemporal dementia: missed targets, dose-limiting nerve inflammation, and a delivery problem nobody has solved.

Thirty Years Filed Under Harmless

P3 was the leftover nobody studied, the scrap from the safe cut of amyloid chemistry. A UC Santa Cruz biochemist says the test tube evidence always said otherwise, and that the amyloid cascade needs a bigger cast list.

The prevention window opens in the late thirties

A Barcelona cohort dates the moment blood and spinal fluid tau in Down syndrome part company with everyone else's: about 37 years for plasma p-tau217. It is the most decision-relevant number in Down syndrome prevention, and it lands years before most trials open their doors.

Approved for Alzheimer's, untested in Down syndrome: what the new review says about the gap

A peer-reviewed review published in April 2026 argues that anti-amyloid antibodies carry higher side-effect risk in adults with Down syndrome, because of denser amyloid in the brain's blood vessels and differences in the blood-brain barrier and immune system. No one with Down syndrome has yet been treated in a completed trial, and the first study is only now due to start.